Table 3 Differences in concomitant treatments between groups
Intensive (%) | Standard (%) | P value | |
|---|---|---|---|
ADVANCE [17] | |||
-Antihypertensive drugs | 88.9 | 88.4 | 0.44 |
-Statins | 45.6 | 47.7 | 0.09 |
-Other cholesterol-lowering drugs | 7 | 7 | 0.90 |
-Aspirin | 57 | 54.9 | 0.02 |
-Other anti-aggregating drugs | 7.1 | 6.2 | 0.07 |
ACCORD [18] | |||
-Anti-hypertensive drugs | 91 | 92 | 0.06 |
-ACEIs | 69.7 | 71.9 | 0.02 |
-Beta blockers | 47.5 | 48.6 | 0.27 |
-Statins | 88 | 87.6 | 0.54 |
-Aspirin | 75.5 | 75.5 | 0.98 |
Kumamoto [16] | 11 | 11 | 1 |
-Statins | 3.6 | 5.4 | 0.66 |
-Fibrates | 0 | 0 | - |
-Aspirin | 1.8 | 3.6 | 0.60 |
- Antiplatelet therapy | 12.7 | 18.1 | 0.45 |
-ACEI | 0 | - | |
-ARB |